Doxofylline and methylprednisolone sodium succinate are stable and compatible under normal injection conditions.
Fan Xu, Enfu Feng, Li Su, Guili Xu
Index: Pak. J. Pharm. Sci. 26(2) , 261-5, (2013)
Full Text: HTML
Abstract
To assess the physical compatibility and chemical stability of doxofylline with methylprednisolone sodium succinate in 0.9% sodium chloride or 5% dextrose injection for intravenous infusion. Twenty mL doxofylline solution (0.74 mg/mL) and 1 mL methylprednisolone sodium succinate solution (0.15 mg/mL) were added into 250 mL polyolefin bags containing 5% dextrose injection or 0.9% sodium chloride injection, and stored for 24 h at 20-25(°)C. Chemical compatibility was measured with high-performance liquid chromatography (HPLC), and physical compatibility was determined visually. The results showed that samples were clear and colorless when viewed in normal fluorescent room light. The pH value exhibited little change. The particulate content of > 25 μm was low and within the specification limit. The particulate content of > 10 μm decreased over time and was similar to the control solution. Analysis of chemical stability revealed that doxofylline is stable with methylprednisolone sodium succinate for up to 24 h, and the degradation of methylprednisolone sodium succinate is unrelated to doxofylline, but is closely related to the pH value of the solution. Doxofylline and methylprednisolone sodium succinate did not affect the stability of each other.
Related Compounds
Related Articles:
Compatibility of intravenous fosaprepitant with intravenous 5-HT3 antagonists and corticosteroids.
2013-09-01
[Cancer Chemother. Pharmacol. 72(3) , 509-13, (2013)]
A misguided 'pill in the pocket' approach with flecainide leading to cardiac arrest.
2012-01-01
[BMJ Case Rep. 2012 , doi:10.1136/bcr-2012-006868, (2012)]
Shoe contact dermatitis: a case report of an acute severe reaction to potassium dichromate.
2012-09-01
[Foot (Edinb.) 22(3) , 141-5, (2012)]
Ex vivomodels to evaluate the role of ocular melanin in trans-scleral drug delivery
2012-08-15
[Eur. J. Pharm. Sci. 46(5) , 475-83, (2012)]
Successful treatment of anti-Caspr2 syndrome by interleukin 6 receptor blockade through tocilizumab.
2013-08-01
[JAMA Neurol. 70(8) , 1056-9, (2013)]